echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > $30 million to help new drugs for nerve pain go clinical.

    $30 million to help new drugs for nerve pain go clinical.

    • Last Update: 2020-08-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Today, BioIntervene, a San Diego-based biopharmaceutical company, announced the completion of a $30 million round of A-round financing to advance the development of its first candidate drug for the treatment of neuropathic pain, BIO-205, as well as the development of a portfolio of A3 adenosine receptors (A3AR) agitants that potentially treat inflammatory and neurodegenerative diseases.
    BioIntervene expects BIO-205 to enter Phase 1 clinical trials in the second half of this year.
    is a complex chronic disease, often referred to as nerve pain.
    it occurs in peripheral nerves and certain brain regions damaged by trauma, disease or toxins.
    common causes of neuropathic pain include surgical or post-traumatic nerve damage, herpes infection, cancer, chemotherapy drugs, and neurological disorders such as multiple sclerosis and metabolic diseases such as diabetes.
    Slayback Pharma completed a $50 million Round B financing Today, Slayback Pharma, a New Jersey-based company, announced a $50 million Round B financing.
    new funding will be used to expand and accelerate its extensive portfolio of generic and specialty pharmaceutical products.
    Slayback focuses on the development of generics and specialty drugs.
    so far, it has developed highly differentiated product pipelines.
    the past two years, Slayback has filed several applications for simplified new drugs, many of which are potential first or second generics on the market.
    january last year, the FDA approved a simplified application for a new drug for its hydroxygesterone Caproate injection to reduce the risk of premature birth in pregnant women.
    is the first and only multi-dose bottled oxyglyceone Caproate injection approved through the FDA's simplified application for the new drug.
    first round of financing of $40 million, Andy Diagnostics, Inc., which specializes in accurate tumor diagnosis, announced the completion of a $40 million financing.
    The first round of financing after the spin-off of ThoughtDi Diagnostics will be mainly used for product development, including follow-up pipeline development of its world-first ANDiS closed automation next-generation sequencing technology (NGS) platform, pipeline development of early oncology diagnostic products based on the exosome platform, and expansion of third-party testing service product pipelines.
    Think Di Diagnostics has two lines of business for third-party medical testing services and IVD (in-body diagnostics) products, with a range of product development pipelines, from early oncology diagnosis to tumor accompanying diagnostics to tumor dynamic monitoring.
    has the world's first closed, fully automated NGS library preparation platform, the world's leading early oncology diagnostic marker (exosome) development platform.
    chinese-first complementary diagnostic and accompanying diagnostic products based on these platforms are in clinical trials or are about to enter clinical trials.
    : $30 Million Series A Financing, BioIntervene Announces, Retrieved Jan. 06, 2020, from a first round of $280 million financing after the spin-off, Retrieved Jan. 06, 2020, from slayback Pharma Announces investment of $50 million by The Everstone Group, Jan. 06, 2020, from.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.